Genmab stock gains as HC Wainwright confirms Buy rating and pipeline outlook strengthens

Published on 09/15/2026 at 19:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genmab stock trades higher after HC Wainwright reaffirmed its Buy rating with a USD 40.00 target as of September 15, 2026. Recent conference comments highlighted 25 percent revenue growth in the first half and multiple late-stage data readouts due in Q4.

Fotorealistisches Biotech-Labor mit Forschern in weißen Kitteln bei Antikörperforschung — Genmab A/S entwickelt Antikörpertherapien in modernen Biotech-Laboren mit Forschern und Präzisionsgeräten, Aktie DK0010272202, Illustration mit AI erstellt.

Genmab A/S (ISIN DK0010272202) stock is drawing fresh attention after HC Wainwright reaffirmed its Buy rating with a target price of USD 40.00 on September 15, 2026, while the shares recently traded around USD 32.47 on Nasdaq, implying upside potential of more than 20 percent according to data summarized by MarketBeat and IT-Boltwise.

Analyst targets support Genmab stock

According to MarketBeat on September 15, 2026, HC Wainwright currently rates Genmab stock Buy with a USD 40.00 price target, while the broader analyst consensus stands at Moderate Buy with an average target of USD 39.50.

As IT-Boltwise reported on September 15, 2026, the confirmed USD 40.00 target implies around 23 percent upside from a Nasdaq reference price of roughly USD 32.47 as of September 14, 2026, while the consensus target of USD 39.50 represents a discount of about 18 percent to that same reference level.

The spread between the current trading region near USD 32.47 and the analyst targets around USD 39.50 to USD 40.00 underlines that the market still prices in a degree of caution despite the fundamentally positive view of most covering houses.

Conference highlights: revenue growth and late-stage pipeline

Beyond the rating, investor focus has shifted to Genmab’s latest strategic update at Morgan Stanley’s 24th Annual Global Healthcare Conference, where management emphasized pipeline breadth and financial momentum.

According to Investing.com on September 15, 2026, Genmab reported that revenue in the first half of 2024 grew by 25 percent year on year, while operating profit rose by 18 percent over the same period, supported by nine distinct revenue-generating medicines.

The same conference summary noted that one of Genmab’s key commercial therapies, EPKINLY, delivered year-on-year revenue growth of 48 percent and quarter-on-quarter growth of 28 percent from the first to the second quarter of 2024, underscoring the product’s role as a major driver in the oncology portfolio.Investing.com

Management stated that Genmab has launched six new phase III trials in 2024 and expects multiple pivotal phase III data readouts in the fourth quarter of 2024, with additional key results anticipated in early 2025, setting up several potential inflection points for the stock.TradingView

Risk view: valuation and overvaluation flags

While the financial and pipeline narrative is constructive, some platforms point to valuation as a potential risk for new investors.

As Investing.com noted on September 15, 2026, Genmab appears on its Most Overvalued list when measured against the platform’s internal fair value estimate, even as the stock only modestly outperformed the broader market in the latest Copenhagen session.

In Copenhagen trading, Genmab shares closed at DKK 2,150.00 on September 15, 2026, up 1.61 percent or 34.00 index points on the OMX Copenhagen 20, suggesting that local investors continue to support the stock despite valuation concerns discussed on some analytics services.Investing.com

Genmab stock price and market data

For international investors, the primary reference for Genmab stock remains its listing on Nasdaq in the United States via the GMAB ticker, quoted in USD, while its Copenhagen listing in DKK serves as an additional regional view.

Per the recent data cited by IT-Boltwise for September 14, 2026, the Nasdaq reference price around USD 32.47 leaves a visible gap to the USD 40.00 HC Wainwright target and the USD 39.50 analyst consensus, framing a potential upside range of roughly 18 to 23 percent if Genmab can deliver on its projected earnings and pipeline milestones.IT-Boltwise

Measured against the Copenhagen close of DKK 2,150.00 as of September 15, 2026, and the Nasdaq region around USD 32.47 on September 14, 2026, Genmab’s valuation already reflects strong expectations for its oncology pipeline, yet the analyst community still sees room for re-rating if upcoming phase III data and revenue growth remain on track.